News

As we mark this awareness day, education and immunization has helped the United States make great strides in preventing the viral disease, but globally more work needs to be done.

Patients treated with oral metronidazole experienced significantly more first-line drug changes compared to those on fidaxomicin; although there were no significant differences observed in the global or clinical cure rate between the 2 treatments.

This antibiotic is the only liquid oral suspension approved in the US.

The findings show that treatment with the COVID-19 oral antiviral can develop into different strains and spread.

Toronto, Canada-based Bluedot offers surveillance tracking information to identify trends for viruses and syndromes efficiently to aid public health officials and other key stakeholders to assess situations and make decisions around this data.

The subject is one where it does not garner the attention of other serious health topics, but key stakeholders say it should.

Earlier this year, the company announced its first foray into these types of infections in developing vaccines for the tickborne infection utilizing its mRNA vaccine platform.

In this week's news, learn about a nurse practitioner's experience as both someone who has battled C diff herself and treated patients with the bacterial infection; a new investigational platform for COVID-19 vaccines; and how chronic hepatitis D is identified as the most severe and progressive form of viral hepatitis.

The federal agency says the data shows immunization reduces hospitalizations by more than 57 percent in first 6 months after birth.

Sam Aitken, PharmD, president-elect of the Society of Infectious Disease Pharmacists (SIDP), discusses how this strategy is one significant part of a complex puzzle to decrease antimicrobial resistance.

The expanded indication to those with severe hepatic impairment has already been granted in the US and EU.

Review of hepatitis D virus describes “unique” biologic characteristics and “ominous” medical effect, but constrained as HBV treatments affect HDV life cycle.

The company’s well-known Singles cheese brand is the focus of the recall.

Vaccitech is using a novel approach to address the virus and create a functional cure.

Mollie Lauck, NP, has both battled C diff herself and treated patients with the bacterial infection. In the second installment of our interview, she talks about her clinical approach to patients who might be considered candidates for C diff and specific strategies for infection prevention.

These novel vaccines are utilizing a self-amplifying messenger RNA (sa-mRNA) vaccine platform. Study data was reported at the ESWI Influenza Conference in Spain.

Long-term follow-up of DAA treatment of HCV infection after liver transplant shows persistent improvement in hepatic function, fibrosis, and survival rate.

There are a number of innovative, virus-targeting agents in development to treat hepatitis C (HCV) and prevent the virus.

Antimicrobials such as clindamycin, cephalosporins, penicillins, and fluoroquinolones have been linked with causing C diff infection in prior research.

Hurricane season is accompanied by an uptick in infectious diseases associated with environmental and water exposures.

A study found variations in treatment initiation, especially showing differences within certain populations, ages, and those with a background of injection drug use.

In this week's news: A CDC committee recommends the updated COVID-19 vaccines; the cost of misinformation during the pandemic; and India is dealing with a Nipah virus outbreak.

Those with certain comorbidities, including peptic ulcer disease and renal failure, were at additional risk of developing C diff infection.

The zoonotic virus has claimed 2 lives as Indian officials work to identify potential contacts and get the virus under control.

A global review demonstrates the potential depth of the impact of the COVID-19 pandemic on ongoing immunization delay and skepticism.

The federal agency says infants of a certain age should receive this monoclonal antibody to protect against the virus.

In our continuing series with members of the Peggy Lillis Foundation, here is an opportunity to hear about people’s experiences, lessons learned, and the new treatments that can lead to hope and not the hopelessness people have been living with during their ordeals.

Several trial participants experienced concerning hepatobiliary events.